The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
Abstract
Purpose: Advanced pancreatic cancer (APC), in addition to its high mortality, accounts for the highest rates of venous thromboembolic events (VTEs). Enoxaparin, a low–molecular weight heparin, is effective in prevention and treatment of VTEs. Some small studies have indicated that this benefit might extend to patients with cancer. Patients and Methods: Patients with histologically proven APC were randomly assigned to ambulant first-line chemotherapy and prophylactic use of enoxaparin or chemotherapy alone to investigate the probable reduction in symptomatic VTEs and the impact on survival. Results: A total of 312 patients were recruited as one of the protocol end points was reached. Within the first 3 months, the numbers of symptomatic VTEs were as follows: 15 of 152 patients in the observation group and two of 160 patients in the enoxaparin group (hazard ratio [HR], 0.12; 95% CI, 0.03 to 0.52; χ 2 P = .001). The numbers of major bleeding events were as follows: five of 152 patients in the observation arm and seven of 160 patients in the enoxaparin arm (HR, 1.4; 95% CI, 0.35 to 3.72; χ 2 P = 1.0). Overall cumulative incidence rates of symptomatic VTEs were 15.1% (observation) and 6.4% (enoxaparin; HR, 0.40; 95% CI, 0.19 to 0.83; P = .01). Progression-free (HR, 1.06; 95% CI, 0.84 to 1.32; P = .64) and overall survival (HR, 1.01; 95% CI, 0.87 to 1.38; P = .44) did not differ between groups. Conclusion: This study demonstrates the high efficacy and feasibility of primary pharmacologic prevention of symptomatic VTEs in outpatients with APC. Treatment efficacy was not affected by simultaneous treatment with enoxaparin in this trial setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 823
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy
Klerk, C. P. W., Smorenburg, S. M., Otten, H.-M., Lensing, A. W. A., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M. E. M., Richel, D. J., van Tienhoven, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.134 · Cited by 596
Cancer and venous thromboembolism
Prandoni, P., Falanga, A., & Piccioli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70207-2 · Cited by 540
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Agnelli, G., George, D. J., Kakkar, A. K., Fisher, W., Lassen, M. R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F., & Turpie, A. G. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108898 · Cited by 531
Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M., & Soyuer, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00871.x · Cited by 455
Lee, A. Y. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., & Levine, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.133 · Cited by 453
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Venous thromboembolism and prognosis in cancer
Khorana, A. A. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2009.12.023 · Cited by 410
Epidemiology and pathophysiology of cancer-associated thrombosis
Noble, S., & Pasi, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605599 · Cited by 396
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 396
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
The incidence of venous thromboembolism among patients with primary lung cancer
CHEW, H. K., DAVIES, A. M., WUN, T., HARVEY, D., ZHOU, H., & WHITE, R. H. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02908.x · Cited by 291
Kleber, F.-X., Witt, C., Vogel, G., Koppenhagen, K., Schomaker, U., & Flosbach, C. W. (2003) · American Heart Journal · doi:10.1067/mhj.2003.189 · Cited by 291
Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
Elting, L. S., Escalante, C. P., Cooksley, C., Avritscher, E. B. C., Kurtin, D., Hamblin, L., Khosla, S. G., & Rivera, E. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1653 · Cited by 269
LAZO‐LANGNER, A., GOSS, G. D., SPAANS, J. N., & RODGER, M. A. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02427.x · Cited by 191
Lyman, G. H. (2011) · Cancer · doi:10.1002/cncr.25714 · Cited by 190
Haas, S. K., Freund, M., Heigener, D., Heilmann, L., Kemkes-Matthes, B., Tempelhoff, G.-F. V., Melzer, N., & Kakkar, A. K. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611433769 · Cited by 180
Model selection in competing risks regression
Kuk, D., & Varadhan, R. (2013) · Statistics in Medicine · doi:10.1002/sim.5762 · Cited by 150
Bullano, M. F., Willey, V. J., Hauch, O., Wygant, G. D., Spyropoulos, A. C., & Hoffman, L. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.8.663 · Cited by 135
Cancer and thrombosis: implications of published guidelines for clinical practice
Khorana, A. A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp068 · Cited by 127
Akl, E. A., Gunukula, S. K., Barba, M., Yosuico, V. E. D., van Doormaal, F. F., Kuipers, S., Middeldorp, S., Dickinson, H. O., Bryant, A., & Schünemann, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006652.pub3 · Cited by 121
Riess, H. B., Pelzer, U., Hilbig, A., Stieler, J., Opitz, B., Scholten, T., Kauschat-Brüning, D., Bramlage, P., Dörken, B., & Oettle, H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-361 · Cited by 81
Self-citationTurpie, A. G. G. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01481-8 · Cited by 72
Methodology for Antithrombotic and Thrombolytic Therapy Guideline Development
Schünemann, H. J., Cook, D., & Guyatt, G. H. (2008) · CHEST Journal · doi:10.1378/chest.08-0666 · Cited by 44
Cited by
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00160-7 · Cited by 486
Self-citation
Metadata
- Authors
- Pelzer, U., Opitz, B., Deutschinoff, G., Stauch, M., Reitzig, P. C., Hahnfeld, S., Müller, L., Grunewald, M., Stieler, J. M., Sinn, M., Denecke, T., Bischoff, S., Oettle, H., Dörken, B., & Riess, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-06-20
- Volume
- 33
- Issue
- 18
- Pages
- 2028-2034
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137283681
- Cited by
- 268
- References
- 38
- FWCI
- 24.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.